leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PRESS RELEASE

...see all

Diabetes drugs market will reach $55.3bn in 2017, with further growth to 2023, predicts visiongain in new report

A new report by visiongain predicts the world market for diabetes medications will reach $55.3bn in 2017. The antidiabetic medicines industry generated $35.6bn in 2012, and its revenues will show strong growth to 2023. That sales forecast and others appear in Diabetes Treatments: World Drug Market 2013-2023, published in April 2013. Visiongain is a business information provider based in London, UK.

The analysis shows human insulins and analogues dominated the antidiabetics market in 2012. Furthermore, that submarket will maintain dominance in the overall diabetes treatments market to 2023. Also, rapid uptake of dipeptidyl peptidase (DPP)-4 inhibitors will stimulate overall revenue growth, owing to their safety profiles and once-daily dosage regimens. The overall diabetes drugs market will thus achieve strong growth to 2013, especially from 2013 to 2017. Its future is promising, based on existing drugs and agents under development. It has strong, broad-ranging R&D.

Visiongain’s study concludes that an increase in the worldwide incidence of type 1 and type 2 diabetes, coupled with increases in obesity, will stimulate growth of the diabetes drugs market. In addition, the new study predicts the market will increase in competition, as the development of type 1 and type 2 diabetes treatments remains profitable for pharmaceutical companies in the short and long term. Also, with companies entering the market from 2013, visiongain predicts more collaborations and alliances. In addition, the diabetes treatment industry and market will encourage combination therapy, with drugs developed as a monotherapy finding it harder in future to gain market share.

Hemant Mistry, a pharmaceutical industry analyst in visiongain, said: “The incidence of diabetes will surge owing to rising levels of obesity and sedentary lifestyles in the global population. Those trends are most evident in emerging countries, such as China and India, which are expected to account for much of the growth of the treatment market. Also, as companies set up operations and facilities in developing countries, to harness the growing patient pool, this increases market competition. That trend helps stimulate innovation and price reductions, an incentive for less-affluent patients in developing countries.

“Furthermore, the diabetes drug market has a strong R&D pipeline. Also, there’s need for new antidiabetic treatments with improved efficacy and safety. In addition, as obesity is closely related to type 2 diabetes, medications that target long-term weight reduction and other related conditions are in high demand. Indeed, owing to the multifactorial aspects of diabetes, drug manufacturers developing medications for associated complications – obesity, heart disease, kidney disease or stroke – are evaluating medicines in clinical trials for treating diabetes. That expanded use of antidiabetics will offer drug manufacturers opportunities to tackle multiple aspects of metabolic disorders and to market drugs to a larger target population, increasing revenues and profits, as well as benefiting patients and healthcare providers. Worldwide, the diabetes drugs market retains great potential for increasing revenues, through technological and commercial progress.”

Visiongain’s report, then, provides revenue forecasts to 2023 at world market, therapeutic submarket and national level. It forecasts world revenues for seven submarkets:

  • Human insulins and analogues
  • Alpha-glucosidase inhibitors
  • Biguanides
  • DPP-4 inhibitors
  • Meglitinides
  • Sulphonylureas
  • Thiazolidinediones.

That investigation also predicts revenues of leading diabetes-treating drugs, including Lantus, NovoLog, Humalog, Levemir and Actos. Research, data and analyses cover activities of Novo Nordisk, Eli Lilly, Sanofi, Bayer, Takeda, Pfizer and other pharmaceutical companies.

The analysis includes researching trends and forecasting revenues in leading national markets. It analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC nations). Also, the study contains interviews with other authorities on diabetes treatment.

Diabetes Treatments: World Drug Market 2013-2023 therefore adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report Diabetes Treatments: The World drug market 2013-2023 please visit

http://www.visiongain.com/Report/1033/Diabetes-Treatments-World-Drug-Market-2013-2023


For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Automotive and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

read more

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close